Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symptom Clusters and Quality of Life in Cervical Cancer Patients During the Perioperative Period: A Longitudinal Study.

Patient preference and adherence·2026
Same author

Perioperative Symptom Trajectories and a Risk Prediction Model for Cervical Cancer: A Prospective Longitudinal Study.

International journal of women's health·2026
Same author

Lamprey 3D single-cell transcriptomics reveals ancestral and specialized features of the vertebrate brain.

Science (New York, N.Y.)·2026
Same author

p53 overexpression counteracts the pro-survival effect of Bcl-2 by restoring MAMs function in cutaneous squamous cell carcinoma.

Cell division·2026
Same author

Herpes simplex virus 1 UL2 protein inhibits RIG-I-like receptor pathway-induced IFN-β activity by disrupting IRF3 activation.

International journal of medical microbiology : IJMM·2026
Same author

Integrative Multi-Omics Analysis Identifies Tissue, Cellular and Splicing Programs Associated with Exercise-Mediated Improvement in Type 2 Diabetes.

Cells·2026

Related Experiment Video

Updated: Jun 13, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Artificial Intelligence in Heart Failure with Preserved Ejection Fraction.

Xinyi Li1,2,3,4, Chunyan Xu1,2,3,4, Wenhui Deng1,2,3,4

  • 1Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, China.

Diagnostics (Basel, Switzerland)
|June 12, 2026
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) and machine learning (ML) can improve the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF). These technologies offer precision medicine approaches but require further validation for clinical integration.

Keywords:
artificial intelligencedeep learningdiagnosisheart failure with preserved ejection fractionmachine learning

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Experiment Videos

Last Updated: Jun 13, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Area of Science:

  • Cardiology
  • Medical Informatics
  • Artificial Intelligence

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is complex, often underdiagnosed, with varied causes and few treatments.
  • Artificial intelligence (AI) and machine learning (ML) can analyze complex health data to address HFpEF challenges.

Purpose of the Study:

  • To review current AI/ML applications in HFpEF.
  • To evaluate AI/ML's potential in diagnosis, sub-phenotyping, risk prediction, and optimizing diagnostics.

Main Methods:

  • Comprehensive literature review of AI/ML in HFpEF.
  • Analysis of supervised, unsupervised, semi-supervised, reinforcement learning, deep learning, and NLP.
  • Focus on external validation studies.

Main Results:

  • AI/ML enhance HFpEF diagnosis accuracy and identify distinct patient phenotypes.
  • AI/ML improve prognostic assessments and diagnostic testing strategies.
  • ML analytics aid patient selection and clinical trial design for HFpEF.

Conclusions:

  • AI is a transformative tool for HFpEF precision medicine.
  • Challenges include model interpretability, bias, and clinical integration.
  • Future work needs external validation and prospective trials for clinical translation.